Ikonisys Announces that Hospitex International Signed Supply Contracts in Italy Marking Growth Potential for the Group
09 Julio 2024 - 10:45AM
Business Wire
Regulatory News:
Ikonisys SA (Euronext Growth Paris: ALIKO), a leading
company in early and accurate cancer diagnosis through cutting-edge
and fully automated solutions for medical analysis laboratories,
today announces that Hospitex International has secured two
contracts for the supply of its products in Italy both for a 4-year
term. The first contract involves the supply of BLOCKfast cytology
kits to the Azienda USL Valle d'Aosta, and the second covers the
supply of single-layer cytology for the ASL TO5 in Moncalieri.
Winning these public tenders is another endorsement of the
quality and reliability of the diagnostic solutions offered by
Hospitex International. The proposed products were selected for
their unique technological features, with significant improvements
compared with the previously used technologies. Those have been
acknowledged by public entities that have underscored the
effectiveness and robustness of Hospitex's solutions, confirming
that the products are extensively tested and certified.
With these new contracts, Ikonisys and Hospitex further
strengthen their positions in the diagnostic technology market,
showing significant growth potential for the Group. The trust
expressed by healthcare institutions through the awarding of public
tenders reflects the growing opportunities in advanced diagnostic
solutions. This success enables Ikonisys to further increase its
position and ultimately the value creation for its shareholders,
thanks to its innovative solutions and leading position in cancer
diagnosis.
As a reminder, BLOCKfast is an innovative kit dedicated to the
preparation of cytological inclusions using a rapid method at room
temperature and a natural replacement for the plasma-thrombin-based
cytological inclusion method, which can no longer be used under
current blood product legislation.
The BLOCKfast kit offers several advantages. The reagents used
are non-flammable, ensuring a safer working environment. The method
allows the simultaneous preparation of multiple samples, thus
optimizing time and improving the efficiency of the diagnostic
process. The colored matrix included in the kit facilitates the
rapid identification of the sample in paraffin and optimizes the
cutting phase, ensuring that the cellular morphology remains
unchanged. Furthermore, BLOCKfast is designed for morphological,
immunohistocytochemical, and molecular analysis, offering a
comprehensive solution for various diagnostic needs.
Securing these two contracts with the Azienda USL Valle d'Aosta
and the ASL TO5 not only strengthens Hospitex's market position but
also represents a high-level endorsement, attesting that the
proposed technologies meet rigorous quality and performance
standards in particular by major healthcare institutions operating
in areas with complex and strategically important diagnostic
needs.
Mario Crovetto, CEO of Ikonisys, and Alessandro Nosei,
COO of Hospitex, commented: "We are proud to have been selected
by local companies, which further confirms the effectiveness of our
diagnostic solutions in the oncology field. Our commitment is even
more enhanced under these circumstances to successfully improving
and streamlining oncology diagnosis. The recent awards, especially
by public and healthcare entities, show that our technologies are
appreciated and recognized for their reliability and
innovativeness. Based on these achievements, we aim at positioning
our future combined entities at the forefront of oncology
diagnosis."
Ikonisys and Hospitex are committed to continuing their path of
innovation, aiming to further expand their offerings and penetrate
new markets. The future strategy includes investments in research
and development, strategic collaborations, and the expansion of the
distribution network to capitalize on emerging market
opportunities.
About Hospitex International
Hospitex International is the world leading company for cytology
standardized monolayer preparations. With CYTOfast it has
re-invented the cytological diagnostics. Hospitex offers a full
range of integrated solutions aimed at streamlining diagnostic
processes in cytology. The global shortage of expertise in
pathology requires tools and technologies that enable diagnostic
safety, efficiency and capacity building. In this area, Hospitex is
recognized as the precision diagnostics player in cytology.
For more information: https://www.hospitex.com/en/
About Ikonisys
Ikonisys SA is a cell-based diagnostics company based in Paris
(France), New Haven (Connecticut, USA) and Milan (Italy)
specialized in the early and accurate detection of cancer. The
company develops, produces and markets the proprietary
Ikoniscope20® and Ikoniscope20max® platforms, fully-automated
solutions designed to deliver accurate and reliable detection and
analysis of rare and very rare cells. Ikonisys has received FDA
clearance for several automated diagnostic applications, which are
also marketed in Europe under CE certification. Through its
breakthrough fluorescence microscopy platform, the company
continues to develop a stream of new tests, including liquid biopsy
tests based on Circulating Tumor Cells (CTC).
For further information, please go to
www.ikonisys-finance.com
Disclaimer
This press release contains forward-looking statements about the
Company's prospects and development. These statements are sometimes
identified by the use of the future tense, the conditional tense
and forward-looking words such as "believe", "aim to", "expect",
"intend", "estimate", "believe", "should", "could", "would" or
"will" or, where appropriate, the negative of these terms or any
other similar variants or expressions. This information is not
historical data and should not be construed as a guarantee that the
facts and data set forth will occur. This information is based on
data, assumptions and estimates considered reasonable by the
Company. It is subject to change or modification due to
uncertainties relating to the economic, financial, competitive and
regulatory environment. This information contains data relating to
the Company's intentions, estimates and objectives concerning, in
particular, the market, strategy, growth, results, financial
situation and cash flow of the Company. The forward-looking
information contained in this press release is made only as of the
date of this press release. The Company does not undertake to
update any forward-looking information contained in this press
release, except as required by applicable law or regulation. The
Company operates in a competitive and rapidly changing environment
and therefore cannot anticipate all of the risks, uncertainties or
other factors that may affect its business, their potential impact
on its business or the extent to which the materialization of any
one risk or combination of risks could cause results to differ
materially from those expressed in any forward-looking information,
it being recalled that none of this forward-looking information
constitutes a guarantee of actual results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240709237037/en/
Hospitex International Marco Testini Investor Relations
marco.testini@hospitex.com
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Louis-Victor Delouvrier/Aurélie Manavarere
Investor Relations ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94
94
NewCap Nicolas Merigeau Media Relations
ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Ikonisys (EU:ALIKO)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024